US EditionPublished • loading... • Updated
Nxera Reports Positive Outcomes for Daridorexant Phase III Insomnia Study
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Clinical Trials ArenaReposted by 
Verdict Hospital
Verdict HospitalNxera reports positive outcomes for daridorexant Phase III insomnia study
Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50 mg, aimed at treating insomnia in adult and elderly patients in South Korea.The post Nxera reports positive outcomes for daridorexant Phase III insomnia study appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
